Effect of acute and chronic administration of tamoxifen on GH response to GHRH and on IGF-I serum levels in women with breast cancer

Salvatore Maria Corsello, Angelina Barini, Carlo Antonio Rota, Silvia Della Casa, Carlo Antonio Barone, Antonino Barbarino, P Putignano, A Barnabei, Mg Migneco, V Vangeli, M Mandalà

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Tamoxifen, an estrogen antagonist, is usually employed in the treatment of breast cancer. Its mechanism of action is not well known because an antiproliferative effect of the drug has been shown also in estrogen receptor negative tumors, most likely mediated by the inhibition of local growth factors and particularly IGF-I. However, the action of tamoxifen on the GH-IGF-I axis is still open to investigation. We have investigated the influence of acute and chronic treatment with tamoxifen on GH response to GHRH and IGF-I serum levels in six postmenopausal women with metastatic breast cancer. A GHRH test (50 microg i.v. at time 0, GH determinations at 0, 15, 30, 60, 90 and 120 min) was performed (a) basally, (b) 3 h after 40 mg oral administration of tamoxifen and (c) after 8 weeks of 20 mg twice a day oral tamoxifen treatment. IGF-I was measured basally and after chronic tamoxifen therapy. No significant modifications in GH response to GHRH were observed after acute or chronic treatment with tamoxifen vs the basal test. On the contrary, chronic tamoxifen treatment induced a significant decrease in serum IGF-I levels. Basal pretreatment levels of 123+/-18 microg/l were suppressed to 65+/-11 microg/l (mean suppression 47%, P < 0.001). These preliminary data confirm the inhibitory effect of tamoxifen on IGF-I production but seem to exclude the possibility that this effect may be due to an inhibition of GH secretion.
Original languageEnglish
Pages (from-to)309-313
Number of pages5
JournalEuropean Journal of Endocrinology
Volume139
Publication statusPublished - 1998

Keywords

  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents, Hormonal
  • Area Under Curve
  • Breast Neoplasms
  • Female
  • Growth Hormone
  • Growth Hormone-Releasing Hormone
  • Humans
  • Insulin-Like Growth Factor I
  • Postmenopause
  • Tamoxifen

Fingerprint

Dive into the research topics of 'Effect of acute and chronic administration of tamoxifen on GH response to GHRH and on IGF-I serum levels in women with breast cancer'. Together they form a unique fingerprint.

Cite this